Thomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.
|Videos|October 19, 2017
Dr. Hoffman-Censits Discusses Immunotherapy in Bladder Cancer
Author(s)Jean Hoffman-Censits, MD
Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.
Advertisement
Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.
For patients with metastatic urothelial carcinoma who are platinum refractory, and for those patients who are not candidates for cisplatin, immunotherapy is the current standard of care.
Advertisement
Related to this article
Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Praful Ravi, MB, BChir, MRCP, discusses the LASER futility readout, PSMA heterogeneity in clear cell RCC, and next steps for radiopharmaceuticals.
Daniel Heng, MD, MPH, FRCPC, discusses data from LITESPARK-011, second-line RCC sequencing, and managing belzutifan-associated anemia and hypoxia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer
2
Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
5